Fine Motor Finesse: 5 Easy Exercises to Increase Hand Coordination and Functional Independence
If you have strong fine motor coordination, you have nothing to fear, but hand weakness and a lack of coordination can severely hamper your quality of life.
5 Exercises for Nimble Fingers
Fingers adept at fine motor control help you function flawlessly. The better your fine motor control is, the better you can manage everyday tasks such as getting dressed, flossing your teeth, chores around the home, functioning at work, or using technology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: Mounjaro sales adverts banned by watchdog Mounjaro patients report unexpected side-effect Who is eligible for free Mounjaro on the NHS? 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: When will Mounjaro be rolled out on the NHS? Travel insurance warning about certain types of policy Warning as Mounjaro and Ozempic sold without prescription Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Yahoo
11 minutes ago
- Yahoo
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
New cash pay program offers Contrave, the #1 branded oral non-GLP-1 weight loss medication brand, for as low as $199 per month* BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance. According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment. "At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health." Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles. "Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication." Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity. For more information or to access the GoodRx Contrave savings card, visit: *Program benefit maximums and eligibility restrictions may apply. About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit About CONTRAVE: CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to Media Contactcurrax@ View original content to download multimedia: SOURCE Currax Pharmaceuticals LLC Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
11 minutes ago
- Yahoo
Percentage of Patients with Telehealth Claims for Mental Health Conditions Increased Nationally and in Every Region in April
Diabetes Entered Top Five Telehealth Diagnostic Categories in South in April for First Time in 2025 NEW YORK, July 15, 2025 /PRNewswire/ -- The percentage of patients with a telehealth claim for a mental health condition increased nationally and in every US census region in April, according to FAIR Health's Monthly Telehealth Regional Tracker. Mental health conditions remained the top diagnostic category for patients with a telehealth claim nationally and in every region. Nationally, patients diagnosed with mental health conditions accounted for 63.0 percent of patients with a telehealth claim in April, up from 61.6 percent in March. The data represent the commercially insured population, excluding Medicare Fee-for-Service, Medicare Advantage and Medicaid. Diabetes mellitus entered the top five telehealth diagnostic categories in the South in April for the first time in 2025. This diagnostic category entered in fifth position, accounting for 2.0 percent of patients with a telehealth claim; encounter for examination, which ranked in third position in March, fell out of the top five in April. In 2025 thus far, diabetes has not ranked among the top five telehealth diagnostic categories in any other region, though it did rank in fourth place nationally in January. UtilizationIn April 2025, the percentage of patients with a telehealth claim decreased nationally and also in the Midwest and South but increased in the Northeast and West. Nationally, the percentage decreased from 14.3 percent in March to 14.2 percent in April, a 0.8 percent drop. In the Midwest, the drop was 5.7 percent and, in the South, it was 1.2 percent. In the Northeast, the percentage of patients with a telehealth claim increased 2.0 percent, and in the West, it increased 0.7 percent. During the same period, telehealth claim lines1 increased as a percentage of all medical claim lines nationally and in every region except the Midwest. Nationally, the percentage increased 1.1 percent, from 4.96 percent in March to 5.01 percent in April. The regional increases varied from 2.6 percent in the Northeast to 1.4 percent in the South and 0.4 percent in the West. In the Midwest, telehealth claim lines decreased 8.3 percent. Urban versus RuralAs in March, in April 2025, telehealth utilization was higher in urban than rural areas nationally and in all four regions.2 Nationally, 14.3 percent of patients in urban areas had a telehealth claim, compared to 7.4 percent in rural areas. The largest difference occurred in the West, where the percentage of urban patients using telehealth (18.6 percent) was 2.3 times the percentage of rural patients (8.1 percent). The smallest difference was found in the Northeast, where the percentage of patients in urban areas using telehealth (16.5 percent) was 1.4 times the percentage of patients in rural areas using telehealth (11.4 percent). Age DistributionAs in March, in April 2025, the age groups 19-30 and 31-40 accounted for the largest percentages of patients with a telehealth claim nationally and in every region. On the national level, 23.3 percent of patients in the age group 19-30 had a telehealth claim, and 22.6 percent of patients in the age group 31-40 had a telehealth claim. Nationally and in every region, the age groups 0-9 and 65 and older accounted for the smallest shares (less than 10 percent each) of patients with a telehealth claim. Procedure CategoriesIn April 2025, psychotherapy services and procedures, and established patient office or other outpatient services (including those for mental health conditions), were, as in March, the top two procedure categories nationally and in every region. The order of the two varied by region and, at the national level, by month. Nationally and in the Midwest and Northeast, psychotherapy services and procedures ranked first in April; nationally, this procedure category accounted for 47.49 percent of patients with a telehealth claim. While this category also ranked first in March in the Midwest and Northeast, it ranked second nationally in March (at 46.1 percent of patients with a telehealth claim). In the South and West, established patient office or other outpatient services ranked first in April, as it had in March. On the national level, established patient office or other outpatient services ranked second in April, accounting for 47.48 percent of patients with a telehealth claim (down from 48.9 percent in March, when it ranked first). About the Monthly Telehealth Regional TrackerLaunched in May 2020 as a free service, the Monthly Telehealth Regional Tracker uses FAIR Health data to track how telehealth is evolving from month to month. An interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions. Each year, the infographic introduces varied views into telehealth utilization. In this sixth iteration of the Monthly Telehealth Regional Tracker, each infographic shows month-to-month changes in telehealth utilization, both through telehealth's percentage of medical claim lines and percent of patients with a telehealth claim; that month's top five diagnostic categories; top five procedure categories; age distribution, which captures the percentage of patients within each age group with a telehealth claim; and urban versus rural telehealth usage. For the Monthly Telehealth Regional Tracker, click here. Follow us on X @FAIRHealth About FAIR HealthFAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 51 billion claim records and is growing at a rate of about 4 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 51 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit Contact:Rachel KentExecutive Director of Communications and MarketingFAIR Health646-396-0795rkent@ 1 A claim line is an individual service or procedure listed on an insurance claim.2 Each telehealth service was attributed to a rural/urban designation in a region based on the patient's medical service area, which FAIR Health determines based on the unique geographical pattern of services utilized by the patient. View original content to download multimedia: SOURCE FAIR Health Sign in to access your portfolio
